Clinical Trials Logo

Spasticity clinical trials

View clinical trials related to Spasticity.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05311215 Active, not recruiting - Spasticity Clinical Trials

Phase II Study to Assess Safety, Pharmacokinetics and Efficacy of SL-1002 for Limb Spasticity

RAISE
Start date: April 22, 2022
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, placebo-controlled single ascending dose escalation study intended to assess the safety, pharmacokinetics and efficacy of single treatment of SL-1002 in patients with mild to severe limb spasticity. The study will enroll 4 cohorts of 8 patients per cohort for a total of 32 patients. Patients will be randomized to receive either SL-1002 or placebo in a 3:1 ratio. The study period will be up to 26 weeks inclusive of a screening period of up to 2 weeks.

NCT ID: NCT04815967 Active, not recruiting - Multiple Sclerosis Clinical Trials

Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity

Start date: November 16, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

Phase 2/3, randomized, double-blind, placebo-controlled, single-treatment, multicenter trial assessing the efficacy and safety of MYOBLOC for the treatment of upper limb spasticity in adults followed by an open-label extension safety trial.

NCT ID: NCT04099667 Active, not recruiting - Spasticity Clinical Trials

Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity

Start date: December 17, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

Phase 2/3, randomized, double-blind, placebo-controlled, single-treatment, multicenter trial assessing the efficacy and safety of MYOBLOC for the treatment of lower limb spasticity, in adults followed by an open-label extension safety trial.

NCT ID: NCT01111435 Active, not recruiting - Spasticity Clinical Trials

A Prospective Study of Spasticity in Individuals With Multiple Sclerosis

Start date: April 2010
Phase: N/A
Study type: Observational

This study is expected to contribute to the body of knowledge on the benefits of individuals with MS taking glatiramer acetate (Copaxone®). If patients have less spasticity when taking glatiramer acetate (Copaxone®), they may be more likely to have an improved quality of life. The hypotheses for this study are: 1. Study participants who transition from interferon therapy to glatiramer acetate (Copaxone®) for a six month period will have a decrease in spasticity. 2. Study participants who transition from interferon therapy to glatiramer acetate (Copaxone®) for a six month period will have a change in perceptions of the impact of spasticity on their lives.